Table 3. Effectiveness and Cost-effectiveness of ART Uptake from Home HTC.
Results are shown for a ten-year time horizon relative to year 2015 with 6% annual drop-out from ART care. Costs and effectiveness are discounted by 3% annually.
| Scenario | Change in HIV incidencea |
Change in HIV prevalencea |
ICER per Infection Averted |
ICER per Death Averted |
ICER per QALY Gained |
|---|---|---|---|---|---|
|
Baseline: ART for 36% of all HIV-positive |
-- | -- | -- | -- | -- |
|
Home HTC: ART for 48% of all HIV-positive |
−33·8% | −4·7% | Dominatedb | $3,290 | $860 |
|
Home HTC + CD4: Additional ART for CD4 350–500 cells/µL |
−40·6% | −6·7% | Dominatedb | $4,070 | $900 |
|
Home HTC + High Viral Load: Additional ART for VL>10,000 copies/mL |
−51·6% | −12·1% | $2,960 | $5,020 | $1,710 |
a
Relative to a No ART counterfactual.
b
A dominated strategy is more costly and less effective or more costly and less cost-effective than a combination of other interventions.